RhumbLine Advisers
NUTX

RhumbLine Advisers’s Nutex Health NUTX Stock Holding History

RhumbLine Advisers’s Portfolio NUTX Stock Details NUTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$541K Buy
5,695
+1,536
+37% +$188K ﹤0.01% 2559
2025
Q4 		$685K Sell
4,159
-740
-15% -$98.2K ﹤0.01% 2457
2025
Q3 		$506K Sell
4,899
-133
-3% -$13K ﹤0.01% 2692
2025
Q2 		$626K Buy
5,032
+4,935
+5,088% +$637K ﹤0.01% 2537
2025
Q1 		$4.56K Hold
97
– – ﹤0.01% 3917
2024
Q4 		$3.07K Hold
97
– – ﹤0.01% 4002
2024
Q3 		$2.1K Sell
97
-1
-1% -$14 ﹤0.01% 4053
2024
Q2 		$580 Hold
98
– – ﹤0.01% 4281
2024
Q1 		$1.41K Hold
98
– – ﹤0.01% 4118
2023
Q4 		$2.63K Hold
98
– – ﹤0.01% 4067
2023
Q3 		$2.97K Sell
98
-99
-50% -$4.78K ﹤0.01% 4066
2023
Q2 		$12.5K Sell
197
-1,373
-87% -$118K ﹤0.01% 3898
2023
Q1 		$238K Sell
1,570
-54
-3% -$10.9K ﹤0.01% 2694
2022
Q4 		$463K Buy
1,624
+1,222
+304% +$235K ﹤0.01% 2497
2022
Q3 		$90K Buy
402
+119
+42% +$50.5K ﹤0.01% 3009
2022
Q2 		$137K Buy
+283
New +$334K ﹤0.01% 3004

Other funds holding NUTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WC
Winmill & Co Rochester, New York $347M AUM 37.48% 1-Year Est. Return

RhumbLine Advisers's NUTX Position: Q1 2026 in Review

RhumbLine Advisers increased its Nutex Health (NUTX) stake by 37% in Q1 2026, buying an estimated $188K and bringing the position to 5,695 shares worth $541K. The position accounts for ﹤0.01% of the portfolio, ranked #2559.

RhumbLine Advisers first reported a position in NUTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $685K in Q4 2025. 129 funds tracked by Wall St. Rank hold NUTX as of Q1 2026.

  • RhumbLine Advisers held 5,695 shares of Nutex Health worth $541K as of Q1 2026.
  • RhumbLine Advisers bought 1,536 Nutex Health shares in Q1 2026, an estimated $188K.
  • Nutex Health made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2559 holding.
  • RhumbLine Advisers first reported a position in Nutex Health in Q2 2022 and has held it in 16 quarters since.
  • RhumbLine Advisers's Nutex Health position peaked at $685K in Q4 2025.
  • 129 funds tracked by Wall St. Rank held Nutex Health as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.